Hugh M Cole Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Hugh M Cole.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Hugh M Cole. Hugh M Cole is SVP, Chief Business Officer in ARIAD PHARMACEUTICALS INC ($ARIA) and Director in CATABASIS PHARMACEUTICALS INC ($CATB) and Chief Business Officer in Jounce Therapeutics, Inc. ($JNCE).
Latest Insider Trading Transactions of Hugh M Cole
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ARIA, CATB, JNCE
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 03 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | A | 11.89 | 53,400 | 634,926 | 53,400 | |
Feb 03 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Grant | A | 0.00 | 26,700 | 0 | 73,889 | 47.2 K to 73.9 K (+56.58 %) |
Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | M | 6.55 | 5,000 | 32,750 | 55,000 | |
Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | M | 4.40 | 5,000 | 22,000 | 39,500 | |
Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 11.95 | 18,000 | 215,100 | 47,189 | 65.2 K to 47.2 K (-27.61 %) |
Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Buy | M | 6.55 | 5,000 | 32,750 | 65,189 | 60.2 K to 65.2 K (+8.31 %) |
Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Buy | M | 4.40 | 5,000 | 22,000 | 60,189 | 55.2 K to 60.2 K (+9.06 %) |
Jan 11 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 7.00 | 3,340 | 23,380 | 55,189 | 58.5 K to 55.2 K (-5.71 %) |
Jan 11 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 6.76 | 2,879 | 19,462 | 58,529 | 61.4 K to 58.5 K (-4.69 %) |
Aug 18 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.71 | 744 | 3,504 | 61,408 | 62.2 K to 61.4 K (-1.20 %) |
Aug 18 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.86 | 454 | 2,206 | 62,152 | 62.6 K to 62.2 K (-0.73 %) |
Aug 18 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.64 | 984 | 4,566 | 62,606 | 63.6 K to 62.6 K (-1.55 %) |
Jun 12 2020 | CATB | CATABASIS PHARMACE ... | Cole Hugh M | Director | Option Exercise | A | 6.17 | 7,500 | 46,275 | 7,500 | |
Feb 04 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | A | 6.55 | 60,000 | 393,000 | 60,000 | |
Feb 04 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Grant | A | 0.00 | 30,000 | 0 | 63,590 | 33.6 K to 63.6 K (+89.31 %) |
Jan 10 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 7.78 | 2,624 | 20,415 | 33,590 | 36.2 K to 33.6 K (-7.25 %) |
Jan 10 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 7.78 | 2,624 | 20,415 | 33,590 | 36.2 K to 33.6 K (-7.25 %) |
Aug 16 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 3.92 | 1,018 | 3,991 | 36,214 | 37.2 K to 36.2 K (-2.73 %) |
Aug 16 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.00 | 648 | 2,592 | 37,232 | 37.9 K to 37.2 K (-1.71 %) |
Aug 16 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.10 | 670 | 2,747 | 37,880 | 38.6 K to 37.9 K (-1.74 %) |
Jul 30 2019 | CATB | CATABASIS PHARMACE ... | Cole Hugh M | Director | Option Exercise | A | 6.82 | 15,000 | 102,300 | 15,000 | |
Feb 05 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | A | 4.40 | 44,500 | 195,800 | 44,500 | |
Feb 05 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Grant | A | 0.00 | 22,250 | 0 | 38,550 | 16.3 K to 38.6 K (+136.50 %) |
Aug 15 2018 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Grant | A | 0.00 | 14,400 | 0 | 16,300 | 1.9 K to 16.3 K (+757.89 %) |
Jun 18 2018 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Buy | P | 7.84 | 1,900 | 14,896 | 1,900 | 0 to 1.9 K |
Feb 05 2018 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | A | 23.98 | 70,500 | 1,690,590 | 70,500 | |
Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | D | 0.00 | 9,788 | 0 | 0 | |
Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | D | 0.00 | 64,733 | 0 | 0 | |
Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | D | 6.51 | 78,000 | 507,780 | 0 | |
Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | D | 6.40 | 100,000 | 640,000 | 0 | |
Feb 16 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Sell | D | 0.00 | 42,834 | 0 | 0 | 42.8 K to 0 (-100.00 %) |
Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | A | 0.00 | 9,788 | 0 | 9,788 | |
Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | M | 0.00 | 12,500 | 0 | 0 | |
Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | M | 0.00 | 6,667 | 0 | 6,667 | |
Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Payment of Exercise | F | 8.69 | 6,249 | 54,304 | 42,834 | 49.1 K to 42.8 K (-12.73 %) |
Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Buy | M | 0.00 | 6,667 | 0 | 49,083 | 42.4 K to 49.1 K (+15.72 %) |
Feb 07 2017 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Buy | M | 0.00 | 12,500 | 0 | 42,416 | 29.9 K to 42.4 K (+41.78 %) |
Jun 29 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | M | 0.00 | 6,666 | 0 | 6,667 | |
Jun 29 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | M | 0.00 | 12,500 | 0 | 0 | |
Jun 29 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Sell | S | 7.05 | 6,012 | 42,385 | 29,916 | 35.9 K to 29.9 K (-16.73 %) |
Jun 29 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Buy | M | 0.00 | 6,666 | 0 | 35,928 | 29.3 K to 35.9 K (+22.78 %) |
Jun 29 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Buy | M | 0.00 | 12,500 | 0 | 29,262 | 16.8 K to 29.3 K (+74.57 %) |
May 02 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | M | 0.00 | 17,334 | 0 | 0 | |
May 02 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Payment of Exercise | F | 7.18 | 5,634 | 40,452 | 16,762 | 22.4 K to 16.8 K (-25.16 %) |
May 02 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Buy | M | 0.00 | 17,334 | 0 | 22,396 | 5.1 K to 22.4 K (+342.43 %) |
Mar 18 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | M | 0.00 | 7,500 | 0 | 7,500 | |
Mar 18 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | A | 0.00 | 15,000 | 0 | 15,000 | |
Mar 18 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Payment of Exercise | F | 6.21 | 2,438 | 15,140 | 5,062 | 7.5 K to 5.1 K (-32.51 %) |
Mar 18 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Buy | M | 6.21 | 7,500 | 46,575 | 7,500 | 0 to 7.5 K |
Mar 09 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | A | 0.00 | 23,400 | 0 | 23,400 | |
Mar 09 2016 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | A | 6.51 | 78,000 | 507,780 | 78,000 | |
Apr 30 2015 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | A | 0.00 | 52,000 | 0 | 52,000 | |
Jun 27 2014 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | A | 6.40 | 100,000 | 640,000 | 100,000 | |
Jun 27 2014 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
Jun 27 2014 | ARIA | ARIAD PHARMACEUTIC ... | Cole Hugh M | SVP, Chief Business ... | Option Exercise | A | 0.00 | 25,000 | 0 | 25,000 |
Page: 1